{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:38:31Z","timestamp":1777631911723,"version":"3.51.4"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>von Willebrand disease (VWD) is the commonest inherited bleeding disorder and results from either a quantitative or qualitative deficiency in the plasma glycoprotein von Willebrand factor (VWF). Recent large cohort studies have significantly enhanced our understanding of the molecular mechanisms involved in the pathogenesis of VWD. In contrast, however, there have been relatively few advances in the therapeutic options available for the treatment of bleeding in patients with VWD. Established treatment options include tranexamic acid, 1-deamino-8-d-arginine vasopressin (DDAVP), and plasma-derived VWF concentrates. In addition, a recombinant VWF has also recently been developed. In this review, we focus on how recent insights into the clinical and molecular aspects underpinning VWD are already beginning to influence treatment in the clinic. For example, a number of different bleeding assessment tools (BATs) have been developed to objectively assess bleeding symptoms in patients with VWD. Interestingly, however, these BAT scores may also have an important role to play in predicting bleeding risk in VWD. Furthermore, recent studies have demonstrated that enhanced VWF clearance plays a critical role in the etiology of both type 1 and type 2 VWD. These findings have direct translational relevance with respect to the use of DDAVP in patients with VWD. As understanding of the mechanisms involved in VWD pathogenesis continues to advance, novel treatment options are likely to emerge. Critically, however, large adequately powered and stratified clinical trials will be required to address the outstanding questions that remain regarding VWD treatment optimization.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.683","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"683-689","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["New treatment approaches to von Willebrand disease"],"prefix":"10.1182","volume":"2016","author":[{"given":"Michelle","family":"Lavin","sequence":"first","affiliation":[{"name":"Haemostasis Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James\u2019s Hospital, Trinity College Dublin, Ireland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Haemostasis Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James\u2019s Hospital, Trinity College Dublin, Ireland;"},{"name":"National Centre for Hereditary Coagulation Disorders, St. James\u2019s Hospital, Dublin, Ireland; and"},{"name":"Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"23","key":"2019111703291339800_B1","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2013-06-498303","article-title":"von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy","volume":"122","author":"Lillicrap","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111703291339800_B2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111703291339800_B3","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"Cumming","year":"2006","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111703291339800_B4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111703291339800_B5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"issue":"20","key":"2019111703291339800_B6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111703291339800_B7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2004.00886.x","article-title":"Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors\u2019 Organization","volume":"10","author":"Pasi","year":"2004","journal-title":"Haemophilia"},{"issue":"4","key":"2019111703291339800_B8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111703291339800_B9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"2019111703291339800_B10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2019111703291339800_B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2011.02573.x","article-title":"A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy","volume":"18","author":"Trigg","year":"2012","journal-title":"Haemophilia"},{"issue":"12","key":"2019111703291339800_B12","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111703291339800_B13","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111703291339800_B14","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"key":"2019111703291339800_B15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jth.12226","article-title":"Clearance of von Willebrand factor","volume":"11","author":"Casari","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111703291339800_B16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jth.12885","article-title":"Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance","volume":"13","author":"Wohner","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111703291339800_B17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111703291339800_B18","first-page":"387","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111703291339800_B19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111703291339800_B20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2019111703291339800_B21","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"2019111703291339800_B22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/asheducation-2009.1.113","article-title":"Optimizing treatment of von Willebrand disease by using phenotypic and molecular data","author":"Rodeghiero","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"6","key":"2019111703291339800_B23","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2009-01-153296","article-title":"How I treat von Willebrand disease","volume":"114","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111703291339800_B24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-08-551960","article-title":"How I treat type 2 variant forms of von Willebrand disease","volume":"125","author":"Tosetto","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111703291339800_B25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"issue":"3","key":"2019111703291339800_B26","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"issue":"2","key":"2019111703291339800_B27","first-page":"345","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"issue":"25","key":"2019111703291339800_B28","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1182\/blood-2015-10-636480","article-title":"Acquired von Willebrand syndrome associated with left ventricular assist device","volume":"127","author":"Nascimbene","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111703291339800_B29","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111703291339800_B30","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/j.1538-7836.2012.04923.x","article-title":"The evolution and value of bleeding assessment tools","volume":"10","author":"Rydz","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111703291339800_B31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2019111703291339800_B32","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111703291339800_B33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jth.12875","article-title":"von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo","volume":"13","author":"Rawley","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111703291339800_B34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","article-title":"Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance","volume":"105","author":"Castaman","year":"2011","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111703291339800_B35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"2019111703291339800_B36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"2019111703291339800_B37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2141.2009.08052.x","article-title":"Platelet von Willebrand factor--structure, function and biological importance","volume":"148","author":"McGrath","year":"2010","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111703291339800_B38","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1182\/blood-2013-04-496851","article-title":"Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis","volume":"122","author":"McGrath","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111703291339800_B39","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1073\/pnas.92.7.2428","article-title":"Platelet von Willebrand factor in inherited and acquired bleeding disorders","volume":"92","author":"Mannucci","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2019111703291339800_B40","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111703291339800_B41","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1182\/blood-2005-09-3605","article-title":"Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor","volume":"107","author":"De Meyer","year":"2006","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/683\/1252108\/hem088403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/683\/1252108\/hem088403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:29:46Z","timestamp":1573979386000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/683\/21130\/New-treatment-approaches-to-von-Willebrand-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.683","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}